Positive outcomes for the use of psilocybin therapy in conjunction with SSRIs have been reported from COMPASS Pathways’ Phase IIb trial.
BetterLife Pharma has announced its first set of positive data showing the anti-depressant effects of an LSD derivative – 2-bromo-LSD (TD-0148A).
Cybin is to meet with the UK’s Medical and Healthcare Products Regulatory Agency (MHRA) to discuss its lead psychedelic candidate CYB003 as a treatment for Major...
The clinical trial is aiming to understand how psilocybin alters brain function in order to improve treatment options for mental illness.
Findings from a new study give insight into how psychedelic substances may relieve symptoms of mental health conditions.
New findings from a citizen science study suggest that microdosing psychedelics could be a valuable tool in the battle against poor mental health.
UK MP Crispin Blunt raised the question of rescheduling psilocybin in Parliament this week after PM Boris Johnson gave Blunt personal reassurance back in May that...
A philanthropic programme with a focus on the psychedelic sector has been launched to harness the power of innovative mental health approaches for social change.
Biotech company Cybin has filed an international patent application related to methods for the delivery of psychedelic medications.
Heroic Hearts UK CEO Keith Abraham discusses his journey to setting up the organisation which aims to help veterans living with PTSD.